“In the investing blog, I seek to help you take sound investment decisions free from emotion by sharing my
objective insights on markets, sectors, and companies.”
Sam Subramanian PhD, MBA, Editor, AlphaProfit MoneyMatters
The favorable dynamics for the Biotechnology industry is attracting investor attention. On the heels of recent gains, there are reasons to be optimistic on continued out-performance. An efficient Food and Drug Administration, progress on extension of new products, trouble in ‘major pharma’ land and reasonable valuation create a favorable milieu for investing in the biotechnology sector. These conditions… Read More »
New ETF Recommendations
Free Investment Newsletter MoneyMatters
Independent analysis of the economy, markets, and sectors
Unbiased ETF, stock, and mutual fund advice and evaluations
Unique insights on emerging profit opportunities and must-know threats
Complimentary access to premium service
Subscription discounts for premium service
Five Smart Ways of Using Sector Funds and ETFs with inside scoop on sector investments
Three Key Mistakes to Avoid when Investing in Sector ETFs
AlphaProfit’s low risk, low effort investment strategy correctly picks up winners for every market environment. It enables AlphaProfit Premium Service Investment Newsletter and its model portfolios to consistently rank #1 in Hulbert Financial Digest.
Receive Free Reports
Sign up for the FREE investment newsletter AlphaProfit Money Matters and immediately receive Two Special Reports
Five Smart Ways to Profit from Sector Funds and ETFs
Avoid Three Common Mistakes ETF Investors Make
Don’t miss timely investment tips. Stay ahead of the market with AlphaProfit MoneyMatters in your inbox
Premium Service Performance
Model Portfolio Annualized Returns
DEC. 1993 to DEC. 2025
Fidelity Agg. Growth
17.6%
Fidelity Growth
14.6%
ETF Agg. Growth
17.4%
ETF Growth
14.4%
ETF Style Rot. (since 2009)
11.3%
S&P 500
10.8%
Stock Recommendation Returns
DEC. 2013 to DEC. 2025
Win Rate
91%
Avg. Holding Period
2.6 months
Avg. Gain
13.1%
MEET
DR. SAM SUBRAMANIAN
Sam Subramanian PhD, MBA has credentials that are the envy of most investment advisers. He combines strong quantitative skills with deep financial expertise and insights on inner workings of Wall Street and corporations. His creativity has helped him win 16 U. S. patents.
Prior to founding AlphaProfit Investments, LLC, Sam worked in positions of increasing responsibility in Finance and Corporate Strategy for McKinsey & Company, Exxon Corporation, and Unocal Corporation. His work centered on Acquisitions and Divestitures, Asset Valuation, Trading, Bankruptcies, and Risk Management.
Well aware of the dismal returns produced by money managers, he was determined to take charge of his own investments. He created a low cost, low effort but high return investing system and rigorously tested it for over two decades using his own money.
This high-performance system helped Sam to quickly become financially independent. Sam still invests his money, using the now award-winning system he created. He shares the unbiased, crystal-clear recommendations and market moves with his subscribers.
DEC. 1993 to DEC. 2025
